Benzinga

Benzinga

Benzinga

viernes, agosto 21

Praxis Precision Medicines Inc

PRAXNASDAQ
Trade with Public
Trade with Public
$375.94
11.363.12%
al cierre: Aug 21, 5:00 PM EST
$375.94
N/A
After hour: 4:00 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Praxis Precision Medicine Analyst Price Targets

Wall Street analyst price targets and consensus rating for Praxis Precision Medicine (PRAX).

Price Target Range — 10 Quarters

Analyst Consensus — 17 Analysts

16Buy
1Sell
Consensus RatingBuy# Analysts17Avg. Consensus PT$539Upside to Avg. PT+43.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026Goldman SachsKevin StrangPT RaiseBuy$470→$575
Aug 7, 2026RBC CapitalLeonid TimashevPT RaiseOutperform$449→$462
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575

Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462

RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Raises Price Target to $362

Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and raises the price target from $323 to $362.
Benzinga Newsdesk

PRO
Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $582

Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $575 to $582.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $810 Price Target

BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $810 price target.
Benzinga Newsdesk

PRO
Goldman Sachs Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $447

Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $447.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved